NRX Pharmaceuticals Inc (NASDAQ: NRXP) stock soared 41% to $12 after the company announced its presentation of data identifying a statistically significant effect of ZYESAMI in preventing the sharp rise in cytokines commonly associated with mortality in patients with COVID-19; in a recently completed phase 2/3 trial, patients treated with placebo experienced a statistically significant elevation in IL-6 cytokine levels whereas those treated with ZYESAMI had a minimal increase in IL-6.
Cytokinetics, Inc. (NASDAQ: CYTK) spikes to multi-year highs after announcing top-line results from Cohorts 1 and 2 of REDWOOD-HCM, a Phase 2 trial of CK-274 for the potential treatment of hypertrophic cardiomyopathy; results, said co, which demonstrated consistent and clinically meaningful reductions in left ventricular outflow tract gradients within two weeks, support progression of CK-274 to a planned Phase 3 registrational trial, expected to start before year-end. Shares of the company are up by 40.56% to $27.03.
Asensus Surgical Inc (NYSEAMERICAN: ASXC) continued volatility; the stock rises after pulling back by approx. 16% over the prior week. The stack surged 15.23% to $2.61. Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery.